Prevention of high-dose chemotherapy-induced cardiotoxicity in high-risk patients by angiotensin-converting enzyme inhibition. - Wikidata - awgldk - TriplyDB

Prevention of high-dose chemotherapy-induced cardiotoxicity in high-risk patients by angiotensin-converting enzyme inhibition.

Prevention of high-dose chemotherapy-induced cardiotoxicity in high-risk patients by angiotensin-converting enzyme inhibition.

http://www.wikidata.org/entity/Q33263478

about

The HER2 Receptor in Breast Cancer: Pathophysiology, Clinical Use, and New Advances in Therapy Cardioprotective interventions for cancer patients receiving anthracyclines Cardioprotective interventions for cancer patients receiving anthracyclines Research progress of cardioprotective agents for prevention of anthracycline cardiotoxicity.Prevention of cardiac dysfunction during adjuvant breast cancer therapy (PRADA): a 2 × 2 factorial, randomized, placebo-controlled, double-blind clinical trial of candesartan and metoprolol Autonomic dysfunction in early breast cancer: Incidence, clinical importance, and underlying mechanisms Cardiac toxicity in cancer survivors Understanding cardiovascular injury after treatment for cancer: an overview of current uses and future directions of cardiovascular magnetic resonance Cardiac effects of anticancer therapy in the elderly Cardiovascular Health of Patients With Cancer and Cancer Survivors: A Roadmap to the Next Level Evaluation and management of patients with heart disease and cancer: cardio-oncology Serum biomarkers for the detection of cardiac toxicity after chemotherapy and radiation therapy in breast cancer patients Use of biomarkers for the assessment of chemotherapy-induced cardiac toxicity.Cardio-Oncology: A Focused Review of Anthracycline-, Human Epidermal Growth Factor Receptor 2 Inhibitor-, and Radiation-Induced Cardiotoxicity and Management Potential Therapeutic Strategies for Hypertension-Exacerbated Cardiotoxicity of Anticancer Drugs Twenty years of anti-HER2 therapy-associated cardiotoxicity Cardiac risk in the treatment of breast cancer: assessment and management.Challenges in acute heart failure clinical management: optimizing care despite incomplete evidence and imperfect drugs Recent Advances on Pathophysiology, Diagnostic and Therapeutic Insights in Cardiac Dysfunction Induced by Antineoplastic Drugs Medical interventions for treating anthracycline-induced symptomatic and asymptomatic cardiotoxicity during and after treatment for childhood cancer.Chemotherapy-Induced Cardiotoxicity: Pathophysiology and Prevention Cancer therapy-induced cardiotoxicity: basic mechanisms and potential cardioprotective therapies.Management of chemotherapy induced cardiomyopathy.Noninvasive diagnosis of chemotherapy related cardiotoxicity Cardio-oncology: a new medical issue.Cardiovascular, diabetes, and cancer strips: evidences, mechanisms, and classifications.Clozapine in a patient with treatment-resistant schizophrenia and hypertrophic cardiomyopathy: a case report.Cardio-oncology in targeting the HER receptor family: the puzzle of different cardiotoxicities of HER2 inhibitors.Diagnostic Strategies for Early Recognition of Cancer Therapeutics-Related Cardiac Dysfunction.Late effects of blood and marrow transplantation.The art of healing broken hearts in breast cancer patients: Trastuzumab and heart failure.Creating a Biomarker Panel for Early Detection of Chemotherapy Related Cardiac Dysfunction in Breast Cancer Patients Assessment of cardiotoxicity with cardiac biomarkers in cancer patients.Cardiovascular Late Effects and Exercise Treatment in Breast Cancer: Current Evidence and Future Directions Pooled analysis of cardiac safety in patients with cancer treated with pertuzumab.Cardiovascular disease in adult survivors of childhood cancer.Network-based analysis reveals distinct association patterns in a semantic MEDLINE-based drug-disease-gene network.Anthracycline-associated cardiotoxicity in survivors of childhood cancer.Cardiovascular toxicities from systemic breast cancer therapy.Anthracycline cardiotoxicity: prevalence, pathogenesis and treatment

P2860

Q21284978-9422FD3C-9178-430F-B9A4-5E2ACA3ED4E4 Q24236338-31403088-FD75-428F-B623-110A819A1A08 Q24243021-FC34EC31-443E-471D-B924-FE33333020C6 Q26742059-040A81DD-A3BA-42CA-8057-78B7E1429BAE Q26768272-960C518E-E05C-420F-B1BF-8079DF90580D Q26795624-AE3CD5F6-B0E4-4995-BE40-64C9FBE87F2D Q26851957-3D5BDA06-E17D-4DA6-B6CD-6C436C29E800 Q26859193-129D38B7-4F69-4C95-8A3B-342C34F2A9B6 Q26863244-9E5DE4E9-C678-493C-8344-B16AC2B6A0B7 Q26864094-54CFE00F-2841-4B3F-AF7D-60AD1354F43F Q26998273-17DFAC64-107A-457E-BA90-9A6E5CE322CD Q27007849-517D5AA1-9639-4537-8A46-28DC4A7EAA99 Q27027354-BCA27E75-67F9-462A-B566-449E0FD8A55E Q28068290-7D633A5A-DA96-4C02-9C84-2C5A436D10A2 Q28070311-99B944CD-454D-40A4-A6ED-04A917B705D7 Q28079391-88F6A6D2-CA70-46AC-9C9D-92AB55FBBD88 Q28081385-FFF3B08E-7606-46D7-BBCC-1AD41C14CCCC Q28085736-10DAE737-A463-440E-A510-AE76C846C855 Q28087776-B5704D0E-A87C-4D83-A0D3-21084DB21D32 Q30248340-C422DE14-7F06-4740-BAE9-A52C9AD63322 Q30399577-EDCE89E0-0328-4D5A-8A30-6B94693FC08B Q30426853-74ED3674-AAC4-4276-82E5-941E2378A6A4 Q30461441-AE018B02-387C-43DE-9B3F-B0491752BF62 Q30461444-EBF9D116-C7A6-4C5A-B3EE-3AE4E7F7FFB0 Q30471284-9C51367C-0552-4F36-8E6E-E9F631A138D3 Q30487342-2881F26B-6EA4-4B0B-B385-6F37C6CE5101 Q30490810-2CD93E34-0671-440A-879E-74346542572D Q33352155-1D362270-BAA9-4C3C-9955-A1DA33E4FC04 Q33565936-7B0AFEC2-1513-43B7-A28A-46914B8DE154 Q33574136-D3C67A0F-4FAD-481C-B2EF-7E1F500602D3 Q33595716-38D6375A-E119-482C-B11F-BC1BFE7E5EA8 Q33816471-A1CEE5EA-946C-4364-8746-E64FA0FAEC35 Q33896047-10FA597D-3759-478E-A19D-3D1008F703BB Q33907581-5B4F461D-A15A-454C-8A33-D1312A046112 Q33930241-B13B4328-81A5-4B5E-8BBD-8E03F1D71985 Q34042984-51B66A24-BB10-4C93-B279-3B08B7424730 Q34064935-FED77D84-C98B-4957-A744-A15E75F6F3A6 Q34626238-3AC46AD6-4AEF-4020-AEF0-6F94687DC70D Q34630349-B9F88AA6-1EE8-4518-A568-58E7955863F3 Q34639876-390FC009-5C40-472C-9860-F3B753B456D0

P2860

Prevention of high-dose chemotherapy-induced cardiotoxicity in high-risk patients by angiotensin-converting enzyme inhibition.

http://www.wikidata.org/entity/Q33263478

description

2006 nî lūn-bûn

@nan

2006 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած

@hyw

2006 թվականի նոյեմբերին հրատարակված գիտական հոդված

@hy

2006年の論文

@ja

2006年論文

@yue

2006年論文

@zh-hant

2006年論文

@zh-hk

2006年論文

@zh-mo

2006年論文

@zh-tw

2006年论文

@wuu

name

Prevention of high-dose chemot ...... -converting enzyme inhibition.

@ast

Prevention of high-dose chemot ...... -converting enzyme inhibition.

@en

Prevention of high-dose chemot ...... -converting enzyme inhibition.

@nl

type

label

Prevention of high-dose chemot ...... -converting enzyme inhibition.

@ast

Prevention of high-dose chemot ...... -converting enzyme inhibition.

@en

Prevention of high-dose chemot ...... -converting enzyme inhibition.

@nl

prefLabel

Prevention of high-dose chemot ...... -converting enzyme inhibition.

@ast

Prevention of high-dose chemot ...... -converting enzyme inhibition.

@en

Prevention of high-dose chemot ...... -converting enzyme inhibition.

@nl

P1433

Q33263478-FB0EF26C-145C-4936-8F54-CE5C4EF12CB2

P1476

Q33263478-8A57EE4F-2764-4642-93F7-046D9CF2E431

P2093

Q33263478-1E0D0B50-95A4-47A1-9524-90FDBDABD25C

Q33263478-2FD2EB2F-BD39-4EAE-88B8-5A61C5D609DE

Q33263478-3E9BBDD4-DCAB-4369-B3FE-B2460E788C36

Q33263478-866B8A44-CACC-40B5-8E20-FCEA83179C8B

Q33263478-943E1BFE-C16F-4BB6-B034-1677E8B9EFD3

Q33263478-C602FC6F-8FD3-4554-BD09-351F7513375C

Q33263478-DF932714-6C81-4EF8-81B4-24D10B8E1EA0

Q33263478-EBD4C428-C265-4A28-8065-9A956F69A08F

Q33263478-FD1F52E3-F773-4369-8B3D-33B36BD8A169

P304

Q33263478-615D53A7-18F2-4D94-B5FC-253383FBAB7E

P31

Q33263478-A892507A-4D5F-4A29-8CCE-2229F77CC268

P356

Q33263478-88D8E9C5-91A6-42AE-8D7D-433B02E6203D

P407

Q33263478-A9E25816-0B66-4A63-A8BD-F2BBA27A468B

P433

Q33263478-E439755C-D081-444F-8C2D-03FB6F7A964D

P478

Q33263478-568CA6B3-247B-4B33-8BAB-9AA21802BAF3

P50

Q33263478-94081DF8-03E7-4361-A4DA-ED7B3D312E25

P577

Q33263478-15CBA3A2-4975-4310-9EB6-22590C76B241

P698

Q33263478-26C6530C-C0C3-42EF-9E52-70A48C18D401

P921

Q33263478-C360AFC1-4665-4FE4-8ECA-F99BD036436B

Q33263478-CDD6AFD9-C555-4F01-A009-27092251D0F9

P356

CIRCULATIONAHA.106.635144

P1433

P1476

Prevention of high-dose chemot ...... -converting enzyme inhibition.

@en

P2093

Alessandro Colombo

http://www.w3.org/2001/XMLSchema#string

Carlo M Cipolla

http://www.w3.org/2001/XMLSchema#string

Cesare Fiorentini

http://www.w3.org/2001/XMLSchema#string

Daniela Cardinale

http://www.w3.org/2001/XMLSchema#string

Fabrizio Veglia

http://www.w3.org/2001/XMLSchema#string

Giuseppina Lamantia

http://www.w3.org/2001/XMLSchema#string

Maria T Sandri

http://www.w3.org/2001/XMLSchema#string

Maurizio Civelli

http://www.w3.org/2001/XMLSchema#string

Nicola Colombo

http://www.w3.org/2001/XMLSchema#string

P304

2474-2481

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1161/CIRCULATIONAHA.106.635144

http://www.w3.org/2001/XMLSchema#string

P407

P433

23

http://www.w3.org/2001/XMLSchema#string

P478

114

http://www.w3.org/2001/XMLSchema#string

P50

Giovanni Martinelli

P577

2006-11-13T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

17101852

http://www.w3.org/2001/XMLSchema#string

P921